Stockscreener 앱 받기
4.735
0.00%
0.005
전일 마감가:
$4.73
열려 있는:
$4.68
하루 거래량:
3.80M
Relative Volume:
2.30
시가총액:
$305.09M
수익:
$317.00K
순이익/손실:
$-53.47M
주가수익비율:
-2.5053
EPS:
-1.89
순현금흐름:
$-49.31M
1주 성능:
-28.55%
1개월 성능:
-24.20%
6개월 성능:
+6.29%
1년 성능:
+136.50%
1일 변동 폭
$4.20
$4.92
1주일 범위
$4.20
$8.48
52주 변동 폭
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
IMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.725 | 305.42M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.69 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
792.69 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
394.17 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
796.74 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
337.73 | 35.45B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Leerink Partners | Outperform |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress - simplywall.st
Can Immuneering Corporation stock outperform in 2025 bull marketJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - ulpravda.ru
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX) - Seeking Alpha
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink - TipRanks
Is Immuneering Corporation stock gaining market shareJuly 2025 Fed Impact & Community Trade Idea Sharing Platform - ulpravda.ru
IMRX Stock Closed Over 20% Higher Today: Here’s Why - Asianet Newsable
Immuneering Pancreatic Cancer Study Reports Promising Survival Results, Yet Shares Decline - Bitget
Why Is Immuneering Stock Trading Lower Today?Immuneering (NASDAQ:IMRX) - Benzinga
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang - TipRanks
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update - TechStock²
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus - Benzinga
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - markets.businessinsider.com
Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3 - Yahoo Finance
IMRX: Atebumetanib plus chemo showed 64% 12-month survival in pancreatic cancer, nearly double standard care - TradingView — Track All Markets
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Immuneering reports 64% survival rate in pancreatic cancer trial - Investing.com
Immuneering stock falls after reporting survival data for pancreatic cancer drug - Investing.com
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data - TipRanks
Immuneering reports 64% survival rate in pancreatic cancer trial By Investing.com - Investing.com Canada
Immuneering Corp Announces Interim Data from Phase 2a Trial - TradingView — Track All Markets
Immuneering reports 64% survival rate at 12 months for pancreatic cancer drug - StreetInsider
Stock Market Update: S&P 500 and Dow Jones Futures Fall — Spotlight on AZZ, Northrop Grumman, Immuneering - Bitget
Immuneering signals fiscal strategy with atebimetinib trial progress - Traders Union
Retail Trends: Will Immuneering Corporation stock see insider buyingCEO Change & Detailed Earnings Play Strategies - moha.gov.vn
All you need to know about Immuneering (IMRX) rating upgrade to buy - MSN
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 - Seeking Alpha
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy - Yahoo Finance
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - Sahm
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP - TipRanks
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial - Nasdaq
Immuneering to provide 12-month survival data for pancreatic cancer drug - Investing.com
Immuneering to provide 12-month survival data for pancreatic cancer drug By Investing.com - Investing.com South Africa
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - The Manila Times
Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell - MarketBeat
Immuneering on track to dose first patient in pancreatic cancer trial in 2026 - MSN
Pancreatic cancer treatment atebimetinib set for Phase 3 trial - Rare Cancer News
Is Immuneering Corporation stock attractive for income investorsJuly 2025 Update & Stepwise Trade Signal Guides - Улправда
Why Immuneering Corporation stock attracts global investorsGlobal Markets & Accurate Buy Signal Notifications - Улправда
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - The Manila Times
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 - Investing.com Australia
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026 - Nasdaq
Immuneering stock rises after FDA and EMA align on Phase 3 trial design By Investing.com - Investing.com South Africa
Immuneering stock rises after FDA and EMA align on Phase 3 trial design - Investing.com
Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan
Immuneering to be added to the Nasdaq Biotechnology Index - TipRanks
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Immuneering (Nasdaq: IMRX) to be added to Nasdaq Biotechnology Index on Dec. 22 - Stock Titan
Analyst Confidence Buoys Immuneering’s Clinical Prospects - AD HOC NEWS
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
자본화:
|
볼륨(24시간):